NEW YORK CITY, NY / ACCESS Newswire / July 24, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc.(NASDAQ:RXST) and certain of ...

RxSight's light adjustable lenses [LAL] continue to gain traction in the $6 billion-plus cataract surgical market. In their Q3 earnings report, RxSight announced that 24,554 LALs were sold in Q3, ...

RxSight’s management is scheduled to present on Tuesday, January 13, 2026, at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time. Interested parties may access a live and archived webcast of the ...

RxSight's Q2 2023 earnings showed an 83% increase in revenue, driven by growth in LDD and LAL earnings. The company has a healthy liquidity position with $147.1M in liquid assets and a reduced term ...

Needham analyst David Saxon reiterated a Buy rating on RxSight, Inc. (NASDAQ:RXST), raising the price target to $34 from $27. The analyst applauds RxSight's improved trading liquidity, track record of ...

ALISO VIEJO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following ...

RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that Shelley Thunen, the Company’s ...

Reported third quarter 2023 revenue of $22.2 million, an increase of 76% compared to the third quarter of 2022, reflecting: The sale of 66 Light Delivery Devices (LDD™s), representing a 35% increase ...